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Abstract	
Objectives	To	evaluate	efficacy	and	long-term	outcome	and	prognostic	factors	of	feline	squamous	cell	carcinomas	(SCC)	treated	with	photodynamic	therapy	(PDT)	
Methods	 Cats	with	histologically	verified	SCC	of	 the	head	and	neck	 received	an	intravenous	 injection	 of	 liposomal	 phosphorylated	 meta-tetra(hydroxylphenyl)chlorine	 (mTHPC)	 and	 4	 hours	 later	 652nm	 light	 was	delivered	 by	 a	 diode	 laser.	 One	 group	 received	 ≤10J/cm2,	 the	 other	 20J/cm2.	Tumor	response	and	duration	were	analyzed	with	stage,	tumor	diameter,	location	and	treatment	intensity	as	prognostic	factors.		
Results	In	total,	63	lesions	in	38	cats	underwent	treatment	with	≤10J/cm	(n=22)	and	20J/cm2	(n=41).	Overall	response	rate	was	84%	(complete	remissions	61%,	partial	 remissions	 22%)	 with	 a	 mean	 progression	 free	 interval	 of	 35	 months	(median	not	reached)	and	a	median	overall	survival	time	of	40	months	(95%CI:33,	
47).	 In	 regard	 to	 tumor	 stage,	 invasiveness	 yielded	 a	 highly	 significant	 worse	outcome	(p<0.017).	All	patients	with	invasive	tumors	showed	progression	at	less	than	6	months.	Larger	lesions	were	associated	with	inferior	control	and	treatment	intensity	and	tumor	location	did	not	influence	response	and	duration.		
Conclusions	and	relevance	PDT	using	systemic	photosensitizer	leads	to	excellent	long-term	 tumor	 control	 in	 the	 majority	 of	 cats.	 However,	 invasive	 and	 large	tumors	had	a	clear	inferior	outcome,	even	if	treated	with	the	higher	dose	intensity.	This	suggests	that	advanced	lesions	are	not	indications	for	photodynamic	therapy.		
			
Introduction	Squamous	cell	carcinomas	(SCC)	are	frequently	occurring	skin	tumors	in	cats.	As	in	humans,	there	is	a	predisposition	for	non-pigmented	skin	areas	and	an	etiologic	correlation	 between	 tumor	 development	 and	 exposure	 to	 ultraviolet	 light	 is	known.	Squamous	cell	carcinomas	are	locally	invasive	but	rarely	metastasise1.	The	spectrum	of	lesions	ranges	clinically	and	histologically	from	actinic	keratosis	(pre-cancerous,	 mild	 dysplasia	 due	 to	 chronic	 sun	 exposure)	 to	 carcinoma	 in	 situ	(cancer	cells	within	their	site	of	origin)	to	invasive	SCC	(penetration	of	basement	membrane)	 (Figure	 1).	 	 The	most	 common	 locations	 for	 cats	 are	 the	 sparsely	haired	areas	of	the	nasal	planum,	eyelids,	and	pinnae2	-	locations	where	surgical	interventions	lead	to	non-optimal	cosmetics	and	function.	Radiation	therapy	has	been	reported	to	achieve	appealing	response	rates	and	control	durations	but	 is	associated	 with	 multiple	 treatment	 sessions	 for	 the	 patient	 and	 should	 be	reserved	for	larger,	more	invasive	stages	of	the	tumor3-6.		Electrochemotherapy,	
cryotherapy	and	strontium-90	plesiotherapy	also	achieve	satisfying	lesion	control	but	 are	 not	widely	 available7-9.	 Photodynamic	 therapy	 (PDT)	 is	 a	 non-invasive	treatment	 modality,	 which	 involves	 the	 use	 of	 a	 photosensitizer,	 light	 and	endogenous	molecular	oxygen	to	kill	cancer	cells.	Previous	studies	have	shown	the	efficacy	of	photodynamic	therapy	to	treat	feline	squamous	cell	carcinoma	as	well	 as	 other	 superficial	 tumors,	 yielding	 a	 superb	 cosmetic	 outcome	 and	satisfying	tumor	control	for	superficial	tumors9-11.	PDT	using	Foslip	(Biolitec	AG	Jena)	or	phosphorylated	meta-tetra(hydroxylphenyl)chlorine	(mTHPC),	a	second-generation	photosensitizer	is	one	of	the	most	common	systemic	sensitizer	for	cats	studied	to	date	and	a	good	tolerability	has	been	described10,	11.		The	purpose	of	this	retrospective	study	was	to	evaluate	the	efficacy	and	long-term	outcome	 of	 systemic	 PDT	 using	 liposomal	 mTHPC	 on	 treatment	 naive	 and	recurrent	cutaneous	carcinomas	in	a	large	cohort	of	cats	and	to	evaluate	tumor	and	 treatment	 variables	 associated	 with	 local	 control	 and	 survival.	 It	 was	hypothesized	 that	 tumor	 size/invasiveness	 would	 be	 one	 of	 the	 strongest	prognostic	factors	regarding	disease	free	interval	(DFI)	and	overall	survival.				
Materials	and	methods	
Animals	 Cats	 with	 histologically	 verified	 carcinoma	 in	 situ	 or	 infiltrative	squamous	 cell	 carcinoma	 were	 entered	 in	 the	 study.	 Previous	 surgical	interventions	 or	 photodynamic	 treatments	 were	 allowed,	 as	 were	 cats	 with	multiple	 lesions.	Tumors	were	staged	according	 to	a	modification	of	 the	World	Health	 Organization	 system	 and	 categorized	 into	 four	 groups.	 The	 first	 group	(T1a)	was	non-invasive	lesions	measuring	<	1.5cm	in	diameter.	The	second	group	
(T1b)	 included	cats	with	 invasive	tumors	<	1.5cm	in	diameter.	The	third	group	(T2a)	were	non-invasive	neoplasms	>	1.5cm	 in	diameter	 and	 the	 fourth	 group	comprised	 invasive	 tumors	 >	 1.5cm	 in	 diameter12.	 Staging	 included	 tumor	cytology	or	histology,	complete	blood	count,	serum	biochemistry,	regional	lymph	node	aspiration	and	thoracic	radiographs.	All	patients	were	treated	at	the	Division	of	 Radiation	 Oncology	 at	 the	 Vetsuisse	 Faculty	 at	 the	 University	 of	 Zurich,	Switzerland,	between	April	2011	and	July	2016.			
Photodynamic	therapy	 Liposomal	 m-THPC	 (Foslip,	 Biolitec	 AG	 Jena)	 was	administered	 intravenously	 over	 five	 minutes	 at	 a	 dosage	 of	 0.15mg/kg	 body	weight.	Six	hours	after	injection,	a	652nm	diode	laser	was	used	as	a	light	source.	The	 light	 was	 delivered	 by	 an	 optical	 quartz	 fiber	 to	 noncontact	 surface	illumination	of	the	visible	tumor	with	an	additional	security	margin	of	5mm.	The	laser	was	adjusted	to	0.5W/cm2	non-thermal	power	density.	One	group	of	patients	received	≤10J/cm2	over	a	treatment	time	of	100	seconds,	the	other	group	20J/cm2	within	200	seconds.	Cats	were	otherwise	protected	from	light	as	much	as	possible.	After	discharge,	owners	were	instructed	to	keep	the	cat	indoors	away	from	strong	light	sources	and	direct	sun	light	exposure	for	approximately	two	weeks.			
Anesthesia	and	pain	management	 Cats	 were	 anaesthetized	 with	 propofol	(Propofol	1%	Fresenius,	Fresenius	Kabi	AG,	Stans)	administered	in	combination	with	midazolam	(Dormicum,	Roche	Pharma	AG,	Reinach)	or	ketamine	(Narketan	10,	 Vetoquinol	 AG,	 Bern)	 to	 effect	 and	were	maintained	 on	 isoflurane/oxygen	(IsoFlo	Abbott,	Wiesbaden).	 For	 pain	management,	 Fentanyl	 7μg/kg	 (Fentanyl	Sintetica,	 Mendrisio)	 was	 injected	 at	 induction,	 10μg/kg	 buprenorphine	
(Temgesic,	 ESSEX	 Chemie	 AG)	 was	 administered	 intravenously	 q8	 hours	overnight	and	at	home	meloxicam	0.1mg/kg	SID	po	(Metacam	for	cats;	Boehringer	Ingelheim)	for	ten	to	fourteen	days	was	prescribed.			
Tumor	response	and	control		 Complete	 response	 (CR)	 was	 defined	 as	complete	 resolution	 of	 all	 lesions.	 Cats	 were	 considered	 to	 have	 had	 a	 partial	response	 (PR)	 when	 there	 was	 at	 least	 a	 50%	 decrease	 in	 the	 size	 of	 the	measureable	tumor	and	as	no	response	when	tumor	size	reduction	was	<50%	or	if	tumor	progression	was	present.	Tumor	size	was	measured	with	calipers.		Patients	were	examined	4	to	8	weeks	after	PDT	and	follow-up	data	was	collected	thereafter	 approximately	 every	 3	 months	 by	 direct	 examination,	 telephone	communication,	 per	 mail	 and	 photos	 either	 with	 the	 owner	 or	 the	 referring	veterinarian.	A	minimum	follow	up	period	of	6	months	was	requested.		
Statistical	analysis	 All	 data	 reported	 is	 given	 by	 mean	 (±standard	 deviation)	unless	otherwise	specified.	Progression	free	interval	(PFI)	was	calculated	from	the	date	of	the	first	PDT	treatment	until	documentation	of	recurrence.	Cases	that	were	lost	to	follow-up	or	that	remained	free	of	recurrence	were	censored	at	the	date	of	the	last	follow-up	evaluation	or	death	of	the	cat.	Median	time	to	recurrence	was	reported	 with	 the	 95%	 confidence	 interval	 of	 95%.	 A	 Kaplan-Meier	 survival	analysis	was	performed	using	SPSS	24	(SPSS	Inc.,	Chicago,	IL,	USA)	to	calculate	PFI	and	overall	survival	time	(OST).	Tumor	response	and	duration	were	analyzed	with	stage,	tumor	diameter,	tumor	location	and	treatment	intensity	with	the	log	rank	statistic	 after	 ensuring	 even	 distribution	 of	 cases	 per	 group.	 Results	 were	considered	significant	at	values	of	P<0.05.			
	 	
	
Results	
Animals	 The	 study	 population	 consisted	 of	 38	 cats	 with	 the	 majority	 being	Domestic	Short	Hair	cats	(n=36),	one	Siamese	and	one	Maine	Coon.	Sixteen	of	the	cats	were	female	spayed,	and	22	were	male	neutered.	The	median	age	at	time	of	treatment	 was	 12.9	 (±	 3.8)	 years	 and	 the	 median	 weight	 was	 4.8	 (±	 1.2)	 kg.	Nineteen	 of	 the	 cats	 had	 one	 lesion,	 13	 had	 two	 and	 6	 cats	 had	 three	 lesions,	resulting	in	a	total	of	63	lesions.	Histologically,	the	majority	(n=50)	was	classified	as	infiltrative	squamous	cell	carcinomas	and	13	as	carcinoma	in	situ	(of	which	7	had	Bowen’s	 disease).	 All	 tumors	were	 located	 on	 the	 head	 and	 neck,	with	 20	located	on	the	eyelid,	19	on	the	nasal	planum,	nine	in	the	temporal	or	ear	base	region	and	 fifteen	 in	 the	 facial	 skin	or	on	 the	neck.	All	 tumors	were	diagnosed	histologically.	Most	tumors	were	non-invasive	with	41	categorized	as	T1a	(<1.5	cm	in	diameter)	and	three	as	T2a	(<1.5cm	in	diameter).	Ten	cats	had	T1b	tumors	(invasive,	 <1.5cm)	 and	 9	 had	 T2b	 tumors	 (invasive,	 >1.5cm).	 Lymph	 node	aspiration	was	performed	in	eleven	cats	and	thoracic	radiographs	were	available	for	all	cats.		All	staged	free	of	metastatic	disease	(N0M0).		
PDT	 Intravenous	liposomal	m-THPC	was	well	tolerated	by	all	patients	and	no	systemic	 adverse	 events	were	noted.	Mild	 acute	 local	 adverse	 effects	 including	erythema	and	edema	(grade	0-1)	were	seen	in	42%	of	cats	shortly	after	PDT	and	resolved	within	 2-7	 days	 post	 therapy.	 In	most	 cats,	 tumor	 necrosis	 and	 scab	formation	at	the	PDT	site	were	observed	within	two	weeks	of	treatment	(Figure	2).	Maximum	response	to	therapy	was	documented	after	8	weeks.	
Post-treatment	nasal	obstruction	and	dyspnea	occurred	 in	one	cat	with	a	 large	T2b	nasal	planum	lesion.	This	patient	was	euthanized	after	1	month	when	there	was	no	improvement	on	supportive	therapy	and	no	tumor	response	noted.			
Tumor	Response	and	Control	 In	 total,	 63	 lesions	 in	 38	 cats	 underwent	treatment	with	≤10J/cm	(n=22)	and	20J/cm2	(n=41).	Overall	response	rate	was	84%	(CR	61%,	PR	22%)	with	a	mean	PFI	of	35mo	(median	not	reached)	(Figure	3)	 and	a	median	OST	of	40mo	 (95%	CI:33,	47).	Tumor	 stage,	maximum	 tumor	diameter	 tumor	 location	 and	 treatment	 intensity	 were	 evaluated	 as	 possible	prognostic	factors.	In	regard	to	tumor	stage,	invasiveness	(T1b	and	T2b	tumors)	yielded	a	significantly	worse	outcome	(p<0.017).	All	patients	with	invasive	tumors	showed	progression	at	 less	 than	6	months.	Also,	 larger	 lesions	were	associated	with	 inferior	 control	 –	 increasing	 tumor	 diameter	 resulted	 in	 decreased	 PFI.	Treatment	intensity	(≤10J/cm2	or	20J/cm2)	and	tumor	location	did	not	influence	response	and	duration	(p>0.05).		
	
Discussion	Results	of	the	present	study	support	previously	reported	data	on	the	role	of	PDT	with	a	systemically	applied	photosensitizer	in	the	treatment	of	feline	SCC10-12.		We	have	 shown	 that	 PDT	 using	 liposomal	 m-TPHC	 results	 in	 good	 control	 of	cutaneous	squamous	cell	carcinomas	in	cats	obtaining	an	overall	response	rate	of	84%	with	a	mean	progression	free	interval	of	35	months.		From	all	prognostic	 factors	analyzed,	 tumor	 invasiveness	and	maximum	 tumor	diameter	were	the	only	ones	shown	to	be	of	significance	for	treatment	response.	Larger	 and	 more	 advanced	 lesions	 (T1b	 and	 T2b)	 responded	 less	 often	 and	
complete	and	relapsed	sooner.	Clearly	one	key	element	in	eradicating	tumor	cells	by	PDT	is	adequate	light	delivery	to	all	areas	of	the	tumor.	Penetration	depth	of	the	photo	activating	 light	 is	not	sufficient	 in	such	 large,	 invasive	 tumors.	 In	 the	present	 study,	 local	 control	 rates	 for	 more	 advanced,	 invasive	 tumors	 were	clinically	 unsatisfactory	 and	 PDT	 should	 not	 be	 recommended	 as	 treatment	choice.	Among	other	factors,	the	success	of	PDT	is	further	dependent	among	other	factors	on	the	total	light	dose	delivered	into	the	target	tissue,	and	treatment	intensity	was	evaluated	for	its	influence	on	outcome13.	No	difference	in	outcome	was	observed	whether	tumors	were	treated	with	≤10J/cm2	or	20J/cm2,	indicating	a	saturation	of	photosensitizer-light	 combination	already	at	 the	 lower	 intensity.	Also	 tumor	location	(pinnae/ear	base,	nasal	planum,	eyelid/peri-orbital,	or	other	cutaneous	sites)	did	not	affect	response	to	PDT	(p>0.05).	Magne	 et	 al.12	 revealed	 that	 PDT	 based	 on	 a	 chlorophyll	 A	 derivative	photosensitizer	HPPH-23	(pyropheophorbide-alpha-hexyl-eter)	was	effective	 in	early	 tumor	 stage	 (small,	 non-invasive)	whereas	 the	 local	 control	 rate	of	 large,	invasive	tumors	was	unacceptable.	In	our	cohort	all	cats	failed	locally	the	latest	within	6	months	of	PDT	if	an	invasive	lesion	had	affected	them.	But	cats	with	non-invasive	 tumors	 remained	 free	 of	 disease	 for	 at	 least	 five	 years	 once	 they	 had	achieved	 complete	 remission.	 In	 the	 same	 study	 of	Magne	 et	 al.	 the	morbidity	associated	with	the	application	of	HPPH-23	was	reported	to	be	high	with	all	cats	treated	 for	T1b	and	T2b	 lesions	 showing	post-treatment	nasal	obstruction	and	dyspnea.	 Further,	 anorexia	 affected	 approximately	 half	 of	 the	 treated	 cats	 and	although	 easily	 controlled	 with	 antibiotics	 secondary	 bacterial	 infection	 was	another	 common	 complication	 reported.	 In	 the	 present	 study,	 PDT	 with	
intravenous	 liposomal	 m-THPC	 was	 well	 tolerated	 by	 the	 majority	 of	 treated	patients.	Local	reactions	following	treatment	with	intravenous	m-THPC	have	to	be	expected	and	mainly	consist	of	scab	formation	and	hypersensitivity	to	light	for	two	weeks.	 In	 the	population	 treated	herein,	 these	 reactions	were	minimal	and	are	easily	managed	 symptomatically	 and	with	owner	 communication.	Only	one	 cat	with	 a	 large	 T2b	 tumor	 lesion	 developed	 stertor	 and	 dyspnea	 due	 to	 nasal	obstruction	 and	 had	 to	 be	 euthanized	 because	 of	 that	 complication.	 No	 other	unacceptable	 side	 effects	were	 observed	 in	 the	 current	 study	 or	 in	 the	 one	 by	Buchholz	et	al.	using	a	similar	treatment	protocol11.	This	study	performed	by	Buchholz	et	al.11	described	an	overall	response	rate	of	even	100%	after	systemic	liposomal	m-THPC.	Four	out	of	twenty	(20%)	treated	cats	had	a	recurrence	within	a	median	of	5.6	months	but	no	impact	of	tumor	stage	was	detected.	However,	 number	of	 treated	 cats	was	 smaller	 than	 in	our	 study,	which	might	have	limited	the	power	of	some	analyses.	Although	initial	response	rates	were	encouraging	in	the	present	study,	systemic	PDT	did	not	 lead	 to	durable	 remission	or	 cure	 in	any	of	 the	 invasive	and	 large	tumors.	We	propose	 to	 treat	 these	 advanced	 tumor	 stages	with	 external	 beam	radiotherapy	which	was	shown	to	be	a	valuable	treatment	option	resulting	in	long	tumor	control.	The	most	recent	study	 from	our	group	evaluated	an	accelerated	radiation	 protocol	 of	 10x4.8	 Gy	 delivered	 twice	 daily	 at	 least	 6hr	 apart	 on	 5	consecutive	days	for	tumor	and	treatment	associated	variables6.		Of	the	forty-four	treated	cats	all	showed	complete	response	to	radiotherapy	with	a	median	DFI	of	916	 days	 and	 a	 one-year	 DFI	 of	 71%.	 Again,	 of	 all	 tested	 variables,	 also	 with	external-beam	radiation	therapy,	tumor	size	showed	a	tendency	to	influence	DFI,	
with	larger	tumors	having	a	greater	risk	of	recurrence	than	smaller	ones.	Acute	and	late	toxicities	were	mild	to	moderate.	Limitations	of	the	current	study	are	certainly	the	retrospective	nature,	the	total	number	 of	 patients	 treated	 and	 the	 number	 of	 cats	 per	 stage.	 Follow-up	information	was	inconsistently	gained	via	direct	examination,	telephone	or	mail	communication	with	 the	 owner	or	 the	 referring	 veterinarian,	what	might	 have	resulted	in	incomplete	data.	Further,	there	was	a	pre-selection	of	cases	as	some	owners	had	refused	multiple	treatment	sessions	under	anesthesia	as	required	for	radiotherapy	or	had	refused	irradiation	because	of	financial	or	logistical	reasons.			PDT	should	be	considered	for	treatment	of	SCC	when	there	are	multiple	lesions,	in	areas	where	surgeries	would	result	 in	morbidity	 (for	example	 the	eyelid)	or	diminished	cosmetic	function	and	when	lesions	are	known	to	be	non-invasive.	The	appealing	advantages	of	PDT	as	opposed	to	other	treatment	modalities	are	a	low	toxicity	profile,	no	cumulative	toxicity	after	multiple	sessions,	that	it	is	performed	in	a	single	treatment	session	and	that	the	cosmetic	outcome	is	very	rewarding.	The	main	limitation	is	the	inability	to	treat	large,	invasive	tumors	effectively.			
Conclusions	PDT	 using	 liposomal	m-THPC	 leads	 to	 excellent	 long-term	 tumor	control	 in	 the	majority	of	cats.	However,	 invasive	and	 large	 tumors	had	a	clear	inferior	outcome,	even	if	treated	with	the	higher	dose	intensity.	This	suggests	that	advanced	lesions	are	not	indications	for	photodynamic	therapy.		
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